) recently announced that data on pipeline candidate Opsumit from
a pivotal phase III study, SERAPHIN (Study with an Endothelin
Receptor Antagonist in Pulmonary arterial Hypertension to Improve
cliNical outcome), was published in the
New England Journal of Medicine.
We note that Actelion is evaluating Opsumit for the treatment
of patients suffering from pulmonary arterial hypertension
The results from the trial (n=742) showed that the risk of a
morbidity/mortality event was cut by 45% in patients who were
administered Opsumit as compared to those on placebo.
Moreover, Opsumit was able to significantly reduce the risk of
morbidity/mortality in both treatment-naïve and
We remind investors that Opsumit is currently under review in
the U.S. and EU.
Apart from PAH, Opsumit is also being evaluated in a pivotal
phase III program in patients suffering from digital ulcers
associated with systemic sclerosis. Results from this study are
expected in 2014. In addition, Opsumit is being evaluated for the
treatment of glioblastoma (phase I).
Meanwhile, Actelion has another candidate, selexipag, which is
being evaluated for the treatment of PAH in a phase III study,
GRIPHON. Results are expected in 2014.
We believe that the successful development and
commercialization of Opsumit and selexipag will further
strengthen Actelion's PAH franchise which currently boasts of
three drugs, Tracleer, Ventavis and Veletri.
Actelion currently carries a Zacks Rank #1 (Strong Buy). Other
stocks that look attractive include
Biogen Idec Inc
Gilead Sciences Inc.
). All three carry a Zacks Rank #1.
AFFYMETRIX INC (AFFX): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
To read this article on Zacks.com click here.